Physician profile
John Colona
NPI 1205880986
$1,075.42
in general payments reported to CMS, 2019-2025
15 companies · $713 in 2025
The $713 reported for 2025 was more than what 93% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $58.38 · 2023: $15.24 · 2024: $289 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.19 | 2025 | |
| Janssen Biotech, INC. | $212.77 | 2024-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $82.62 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $72.13 | 2025 | Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.78 | 2024-2025 | Xifaxan |
| Boston Scientific Corporation | $58.38 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $57.28 | 2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $41.42 | 2025 | |
| Lilly USA, LLC | $34.91 | 2024-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $21.91 | 2024 | Rebyota |
| Biocon Biologics INC | $21.00 | 2025 | Yesintek |
| Rayner Intraocular Lenses Limited | $20.91 | 2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Madrigal Pharmaceuticals | $18.06 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $16.82 | 2024 | Voquezna |
| Inspire Medical Systems, INC. | $15.24 | 2023 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Colona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.